Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2575727 | PMC |
| http://dx.doi.org/10.1172/jci37749 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial.
JAMA Dermatol
October 2024
Alliance Clinical Trials and Probity Medical Research, Waterloo, Ontario, Canada.
Importance: New, effective, and well-tolerated oral therapies are needed for treating psoriasis. Zasocitinib, a highly selective allosteric tyrosine kinase 2 (TYK2) inhibitor, is a potential new oral treatment for this disease.
Objective: To assess the efficacy, safety, and tolerability of zasocitinib in patients with moderate to severe plaque psoriasis.
Article Synopsis
- Cendakimab is a treatment that targets and inhibits interleukin-13 (IL-13), which plays a role in the development of atopic dermatitis (AD), and is being studied for its effectiveness in treating this condition compared to a placebo.
- A phase 2 clinical trial involved 221 adult participants with moderate to severe AD who had not responded well to topical treatments, with patients receiving different doses of cendakimab or a placebo from May 2021 to November 2022.
- Results showed that the highest dose of cendakimab (720 mg, once weekly) significantly improved eczema symptoms compared to placebo, while other dosages did not achieve statistical significance, indicating potential for cend
Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2).
Dermatol Ther (Heidelb)
May 2024
Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Article Synopsis
- Atopic dermatitis (AD) significantly impacts quality of life due to intense itching and other symptoms; this study investigates the effects of the oral medication upadacitinib on patients with moderate-to-severe AD over 16 weeks.
- The analysis included data from 1,683 patients in clinical trials, showing that those taking upadacitinib experienced notable improvements in itching and other quality of life indicators compared to those on a placebo, starting as early as one week and continuing through the study period.
- Results indicated that patients on upadacitinib reported better outcomes in areas like skin pain, sleep, daily activities, emotional well-being, and overall treatment satisfaction, suggesting this medication could be an effective option for managing AD
Still having his say: David Yoder's legacy in AAC.
Augment Altern Commun
June 2024
Departments of Communication, Psychology, and Communication Sciences & Disorders, Georgia State University, Atlanta, GA, USA.
On February 2 2023, one of the guiding lights in the field of augmentative and alternative communication (AAC) for more than four decades, David E. Yoder, passed away at the age of 90. A voracious reader and gifted storyteller, David was particularly fond of a quote from George Bernard Shaw's , "You see things; and you say 'Why?' but I dream things that never were; and I say 'Why not?'" That vision led him to take on multiple leadership roles and influence the field of AAC in multiple ways.
View Article and Find Full Text PDFGeorge Edward Hoch (1931-2023): a great photosynthesis scholar, a real family man, and a wonderful friend to many.
Photosynthetica
October 2023
Department of Plant Biology, Department of Biochemistry, and Center of Biophysics and Quantitative Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA.
We present here a tribute to George E. Hoch, one of the top leaders in deciphering the primary steps of oxygenic photosynthesis. After providing his academic background, we discuss his selected research on the photoreactions of photosynthesis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!